Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): Affinities, potencies and selectivity in multiple native and BnR transfected cells

Peptides

Volumn 31, Issue 8, 2010, Pages 1569-1578

  Sancho, Veronica ^a   Moody, Terry W ^a   Mantey, Samuel A ^a   Florio, Alessia Di ^a   Uehara, Hirotsugu ^a   Coy, David H ^b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Agonist; Bombesin; Gastrin releasing peptide; Neuromedin B; Receptor

Indexed keywords

BOMBESIN RECEPTOR; BOMBESIN RECEPTOR SUBTYPE 3; BOMBESIN RECEPTOR SUBTYPE 3 AGONIST; HORMONE RECEPTOR STIMULATING AGENT; PHOSPHOLIPASE C; PROTEIN KINASE D; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL GROWTH; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BOVINE RESPIRATORY SYNCYTIAL VIRUS;

EID: 78249247696     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.04.023     Document Type: Article

References (65)

1. Benya RV, Fathi Z, Pradhan T, Battey JF, Kusui T, Jensen RT. Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization and growth: possible role of cAMP. Mol Pharmacol 1994; 46(2):235-245
2. Benya RV, Kusui T, Pradhan TK, Battey JF, Jensen RT. Expression and characterization of cloned human bombesin receptors. Mol Pharmacol 1995; 47:10-20.
3. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, et al. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol 1992; 42(6):1058-1068
4. Berna MJ, Hoffmann KM, Tapia JA, Thill M, Pace A, Mantey SA, et al. CCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKCindependent pathways. Biochim Biophys Acta 2007; 1773:483-501.
5. Boyle RG, Humphries J, Mitchell T, Showell GA, Apaya R, Iijima H, et al. The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3). J Pept Sci 2005; 11:136-141
6. Coll AP. Treating Obesity? It's in the Bag! Cell Metab 2010; 11:95-96
7. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, et al. BRS-3: novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993; 268(8):5979-5984
8. Fleischmann A, Laderach U, Friess H, Buechler MW, Reubi JC. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000; 80:1807-1817
9. Gonzalez N, Hocart SJ, Portal-Nunez S, Mantey SA, Nakagawa T, Zudaire E, et al. Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor. J Pharmacol Exp Ther 2008; 324:463-474
10. Gonzalez N, Mantey SA, Pradhan TK, Sancho V, Moody TW, Coy DH, et al. Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides 2009; 30:1473-1486
11. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 2008; 15:58-64.
12. Guan XM, Chen H, Dobbelaar PH, Dong Y, Fong TM, Gagen K, et al. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab 2010; 11:101-112
13. Hou X, Wei L, Harada A, Tatamoto K. Activation of bombesin receptor subtype-3 stimulates adhesion of lung cancer cells. Lung Cancer 2006; 54:143-148
14. Jensen RT. Receptors on pancreatic acinar cells. In: Johnson LR, Jacobson ED, Christensen J, Alpers DH, Walsh JH, editors. Physiology of the gastrointestinal tract, vol.2, Third ed. New York: Raven Press; 1994. p. 377-446.
15. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev 2008; 60:1-42.
16. Jensen RT, Coy DH, Saeed ZA, Heinz-Erian P, Mantey S, Gardner JD. Interaction of bombesin and related peptides with receptors on pancreatic acini. Ann NY Acad Sci 1988; 547:138-149
17. Jensen RT, Moody T, Pert C, Rivier JE, Gardner JD. Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. Proc Natl Acad Sci USA 1978; 75:6139-6143
18. Jensen RT, Moody TW. Bombesin-related peptides and neurotensin: effects on cancer growth/proliferation and cellular signaling in cancer. In: Kastin AJ, editor. Handbook of biologically active peptides. Amsterdam: Elsevier; 2006. p. 429-434
19. Ladenheim EE, Hamilton NL, Behles RR, Bi S, Hampton LL, Battey JF, et al. Factors contributing to obesity in bombesin receptor subtype-3-deficient mice. Endocrinology 2008; 149:971-978
20. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol 1998; 123:1655-1665
21. MacEwan DJ, Kim GD, Milligan G. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma×glioma hybrid NG108-15 cells transfected to express differing levels of the human β2-adrenoceptor. Mol Pharmacol 1995; 48:316-325
22. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T. Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 2001; 276:28083-28091
23. Mantey S, Frucht H, Coy DH, Jensen RT. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes. Mol Pharmacol 1993; 45:762-774
24. Mantey SA, Coy DH, Entsuah LK, Jensen RT. Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3. J Pharmacol Exp Ther 2004; 310:1161-1170
25. Mantey SA, Coy DH, Pradhan TK, Igarashi H, Rizo IM, Shen L, et al. Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3. J Biol Chem 2001; 276:9219-9229
26. Mantey SA, Gonzalez N, Schumann M, Pradhan TK, Shen L, Coy DH, et al. Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands. J Pharmacol Exp Ther 2006; 319:980-989
27. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan TK, et al. Discovery of a high affinity radioligand for thehumanorphan receptor, bombesin receptor subtype 3, which demonstrates it has a unique pharmacology compared to other mammalian bombesin receptors. J Biol Chem 1997; 272(41):26062-26071
28. Matsumoto K, Yamada K, Wada E, Hasegawa T, Usui Y, Wada K. Bombesin receptor subtype-3 modulates plasma insulin concentration. Peptides 2003; 24:83-90.
29. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A, et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J BiolChem 2004; 279:23580-23589
30. Nakamichi Y, Wada E, Aoki K, Ohara-Imaizumi M, Kikuta T, Nishiwaki C, et al. Functions of pancreatic beta cells and adipocytes in bombesin receptor subtype-3-deficient mice. Biochem Biophys Res Commun 2004; 318:698-703.
31. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, et al. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 1997; 390(6656):165-169
32. Porcher C, Juhem A, Peinnequin A, Bonaz B. Bombesin receptor subtype-3 is expressed by the enteric nervous system and by interstitial cells of Cajal in the rat gastrointestinal tract. Cell Tissue Res 2005; 320:21-31.
33. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 1998; 343:275-287
34. Reubi JC, Wenger S, Schumuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radoligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002; 8:1139-1146
35. Rowley WH, Sato S, Huang SC, Collado-Escobar DM, Beaven MA,Wang LH, et al. Cholecystokinin-induced formation of inositol phosphates in pancreatic acini. Am J Physiol 1990; 259:G655-65.
36. Rozengurt E, Guha S, Sinnett-Smith J. Gastrointestinal peptide signalling in health and disease. Eur J Surg Suppl 2002:23-38.
37. Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, et al. Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3. J Biol Chem 1998; 273:13613-13624
38. Ryan RR, Weber HC, Mantey SA, Hou W, Hilburger ME, Pradhan TK, et al. Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells. J Pharmacol Exp Ther 1998; 287:366-380
39. Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, et al. Characterization of the bombesin-like peptide receptor family in primates. Genomics 2004; 84:139-146
40. Schulz S, Rocken C, Schulz S. Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies. Virchows Arch 2006; 449:421-427
41. Shan L, Emanuel RL, Dewald D, Torday JS, Asokanathan N, Wada K, et al. Bombesin-like peptide receptor gene expression, regulation, and function in fetal murine lung. Am J Physiol (Lung Cell Mol Physiol) 2004; 286:L165-73.
42. Tan YR, Qi MM, Qin XQ, Xiang Y, Li X, Wang Y, et al. Wound repair and proliferation of bronchial epithelial cells enhanced by bombesin receptor subtype 3 activation. Peptides 2006; 27:1852-1858
43. Tan YR, Qin XQ, Xiang Y, Yang T, Qu F, Wang Y, et al. PPARalpha and AP-2alpha regulate bombesin receptor subtype 3 expression in ozone-stressed bronchial epithelial cells. Biochem J 2007.
44. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and densitydependent signaling pathways. Endocrinology 1997; 138:4109-4122
45. 2+- and PKC-independent mechanism which is partially mediated by the small GTP-binding protein rho. Gastroenterology 1996; 110(A1127). Ref Type: Abstract.
46. Tsuda T, Kusui T, Hou W, Benya RV, Akeson MA, Kroog GS, et al. Effect of gastrinreleasing peptide receptor number on receptor affinity, coupling, degradation and receptor modulation. Mol Pharmacol 1997; 51(5):721-732
47. Valverde AM, Sinnett-Smith J, Van Lint J, Rozengurt E. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci USA 1994; 91:8572-8576
48. Van Lint J, Rykx A, Maeda Y, Vantus T, Sturany S, Malhotra V, et al. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol 2002; 12:193-200.
49. Wada E, Way J, Lebacq-Verheyden AM, Battey JF. Neuromedin B and gastrinreleasing peptide mRNAs are differentially distributed in the rat nervous system. J Neurosci 1990; 10:2917-2930
50. Waldron RT, Rey O, Iglesias T, Tugal T, Cantrell D, Rozengurt E. Activation loop Ser744 and Ser748 in protein kinase D are transphosphorylated in vivo. J Biol Chem 2001; 276:32606-32615
51. Wang LH, Coy DH, Taylor JE, Jiang NY, Kim SH, Moreau JP, et al. Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with a potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry (Mosc) 1990; 29(3):616-622
52. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, et al. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem 1990; 265(26):15695-15703
53. Wang Y, Zhang M, Tan Y, Xiang Y, Liu H, Qu F, et al. BRS-3 activation transforms the effect of human bronchial epithelial cells from PGE2 mediated inhibition to TGF-beta1 dependent promotion on proliferation and collagen synthesis of lung fibroblasts. Cell Biol Int 2007; 31:1495-1500
54. Weber D, Berger C, Eickelmann P, Antel J, Kessler H. Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J Med Chem 2003; 46:1918-1930
55. Weber D, Berger C, Heinrich T, Eickelmann P, Antel J, Kessler H. Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3. J Pept Sci 2002; 8:461-475
56. Weber HC. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes 2009; 16:66-71.
57. Weber HC, Walters J, Leyton J, Casibang M, Purdom S, Jensen RT, et al. A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells. Eur J Pharmacol 2001; 412:13-20.
58. Williams BY, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function. Cancer Res 1994; 54(3):818-824
59. Wu JM, Hoang DO, Feldman RI. Differential activation of human gastrinreleasing peptide receptor-mediated responses by bombesin analogs. Mol Pharmacol 1995; 47(4):871-881
60. Wu JM, Nitecki DE, Biancalana S, Feldman RI. Discovery of high affinity bombesin receptor subtype 3 agonists. Mol Pharmacol 1996; 50(5):1355-1363
61. Yamada K, Ohki-Hamazaki H, Wada K. Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin receptor subtype-3 (BRS-3) deficient mice. Physiol Behav 2000; 68:555-561
62. Yamada K, Santo-Yamada Y, Wada E, Wada K. Role of bombesin (BN)-like peptides/receptors in emotional behavior by comparison of three strains of BN-like peptide receptor knockout mice. Mol Psychiatry 2002; 7(113-7):6.
63. Yamada K, Wada E, Imaki J, Ohki-Hamazaki H, Wada K. Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese (bombesin receptor subtype-3-deficient) mice. Physiol Behav 1999; 66:863-867
64. Zhang L, Nothacker HP, Wang Z, Bohn LM, Civelli O. Pharmacological characterization of a selective agonist for bombesin receptor subtype-3. Biochem Biophys Res Commun 2009; 387:283-288
65. s-coupled receptors and dependent on receptor density. Mol Pharmacol 1994; 46(3):460-469